Parallel Advisors LLC Has $2.05 Million Position in Novo Nordisk A/S $NVO

Parallel Advisors LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 27.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 55,856 shares of the company’s stock after purchasing an additional 12,138 shares during the period. Parallel Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,053,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the 4th quarter worth approximately $25,000. WealthCollab LLC boosted its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. Maseco LLP bought a new position in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S during the fourth quarter worth $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.4%

Shares of NVO stock opened at $49.40 on Wednesday. The company has a market capitalization of $220.58 billion, a P/E ratio of 11.60, a P/E/G ratio of 4.53 and a beta of 0.77. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $46.21 and a 200 day moving average price of $45.77.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Research analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NVO shares. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk received a boost from continued momentum behind Wegovy, including reports that the newly approved oral version in Europe could expand the drug’s reach and improve the company’s competitive position. Wegovy Pill in Europe – Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
• Positive Sentiment: Citi reportedly raised its price target on Novo Nordisk ahead of earnings, citing stronger-than-expected Wegovy pill launch trends and higher sales and profit estimates, which supports a more bullish near-term outlook. Citi lifts Novo Nordisk target on strong GLP-1 pill launch
• Positive Sentiment: Novo Nordisk also announced progress in China through Fangzhou’s launch of Kyinsu, a once-weekly basal insulin/GLP-1 combination therapy, broadening its international diabetes footprint. Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
• Neutral Sentiment: The company said it is continuing a DKK 15 billion share repurchase program, which can help offset dilution and signal management confidence, but is not a major new catalyst on its own. Novo Nordisk A/S – share repurchase programme
• Negative Sentiment: The biggest near-term headwind is Novo Nordisk’s lawsuit against Eli Lilly, alleging misleading advertising and outdated clinical data in campaigns for Zepbound and Mounjaro. While the suit aims to protect Novo’s brands, it also highlights intensifying competition in obesity drugs and adds litigation risk. Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.